Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

Discover key insights from Roivant Sciences' Q4 2024 earnings call. Learn about their robust pipeline, pivotal 2025 milestones, and capital strength.

Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

Shares of Immunovant, Inc. (IMVT) traded 2% higher on Thursday morning after the company reported a narrower-than-expected ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder driven by the classical pathway that causes progressive muscle weakness. Over 100,000 people in the US are living with gMG and ...

at the influential 15 th Annual Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders, taking place from 13-15 May in The Hague, Netherlands.

The Company continues to progress its Phase 2b clinical study in generalized myasthenia ... gravis (MG) and preclinical evidence in spinal muscular atrophy, Charcot-Marie Tooth (CMT) disease ...

Generalized myasthenia gravis is a chronic autoimmune disease that J&J estimates affects around 700,000 people worldwide. In this disease, the body makes auto-antibodies that target proteins at ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include Myasthenia Gravis Activities ... be a classical pathway-driven disease,” said Marino Garcia ...